Floatz logo

Belinostat

Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 cohort.

Asset / SponsorPhaseRating
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 3BB
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 2BB
Azacitidine
National Cancer Institute (NCI)
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB

View all 34 →

Same molecule, other indications

Belinostat is also rated in:

HIV InfectionsDormant
BB
Indicative ·
67 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
diffuse large B-cell lymphomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →